Evidence map›Paper›PMID 26097874›Full record

ArticleOncoscience2015

Epigenetic silencing of S100A2 in bladder and head and neck cancers.

Juna Lee, Piotr T Wysocki, Ozlem Topaloglu, Leonel Maldonado, Mariana Brait, Shahnaz Begum, David Moon, Myoung Sook Kim, Joseph A Califano, David Sidransky and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Influence of S100A2 in Human Diseases.Diagnostics (Basel, Switzerland) · 2022
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Juna LeeGraduate Program in Human Genetics and Molecular Biology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Piotr T WysockiDepartment of Otolaryngology - Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ozlem TopalogluDepartment of Otolaryngology - Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Leonel MaldonadoDepartment of Otolaryngology - Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mariana BraitDepartment of Otolaryngology - Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Shahnaz BegumDepartment of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
David MoonDepartment of Otolaryngology - Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Myoung Sook KimDepartment of Otolaryngology - Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Joseph A CalifanoDepartment of Otolaryngology - Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA ; Milton J. Dance Head and Neck Center. Greater Baltimore Medical Center, Baltimore, Maryland, USA.
David SidranskyDepartment of Otolaryngology - Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA ; Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mohammad O HoqueDepartment of Otolaryngology - Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA ; Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA ; Department of Urology, Johns Hopkins University, Baltimore, Maryland, USA.
Chulso MoonGraduate Program in Human Genetics and Molecular Biology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA ; Department of Otolaryngology - Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA ; Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins Medicine · USJohns Hopkins University · USSidney Kimmel Comprehensive Cancer Center · US

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI Richard Bruce Roden · 2003 to 2026
$53.5M
Tumor Suppressor Gene Promoter Hypermethylation for Detection of Head/Neck CancerP50CA096784 · NCI · JOHNS HOPKINS UNIVERSITY · PI SIDRANSKY, DAVID · 2002 to 2006
$11.3M
Discovery and Characterization of Methylation MarkersR01CA163594 · NCI · JOHNS HOPKINS UNIVERSITY · PI SIDRANSKY, DAVID · 2012 to 2016
$1.8M
NCI NIH HHS P50 CA096784NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA163594
6 · The paper itself

Abstract

S100A2, a member of the S100 protein family, is known to be downregulated in a number of human cancers, leading to its designation as a potential tumor suppressor gene. Here, we investigated the expression and methylation status of S100A2 in head&neck and bladder cancer. Reduced mRNA and protein expression was observed in 8 head&neck and bladder cancer cell lines. To explore the mechanism responsible for the downregulation of S100A2, we treated six cell lines with 5-aza-2'-deoxycytidine. We found S100A2 is silenced in association with aberrant promoter-region methylation and its expression is restored with 5-aza-2'-deoxycytidine treatment. Of 31 primary head&neck cancer cases and 31 bladder cancer cases, promoter methylation was detected in 90% and 80% of cases, respectively. Interestingly, only 1/9 of normal head&neck tissues and 2/6 of normal bladder tissues showed promoter methylation. S100A2 promoter methylation can be detected in urine and is more frequent in bladder cancer patients than in healthy subjects (96% vs 48% respectively). Moreover, increased methylation of S100A2 is linked to the progression of the tumor in bladder cancer (p<0.01). Together, this data shows that methylation-associated inactivation of S100A2 is frequent and may be an important event in the tumorigenesis of head&neck and bladder cancer.

Indexed as

bladder cancerepigeneticshead and neck cancermethylationS100A2

Identifiers

PMID26097874
PMCPMC4468326
OpenAlexW2188485501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.